title: Botulinum toxin in motor disorders: practical considerations with emphasis on interventional neurophysiology.
abstract: After a brief review of the pharmacological properties of the botulinum toxin (BT), its mechanism of action on the nerve endings of the neuromuscular junctions, and the general therapeutic principles and adverse side effects, we discuss the advantages of interventional neurophysiology for the treatment of focal motor disorders by means of botulinum toxin A (BTA) muscle infiltration. Electromyography (EMG) provides a valuable objective information in the diagnosis of many motor disturbances and enables the precise identification of the muscles that contribute to the abnormal movement or posture. The use of EMG guidance for BTA injection seems advisable in every muscle but it become indispensable in those difficult to access, deeply located or partially atrophied by previous toxin infiltrations. The EMG study also serves to localise the areas with the highest abnormal activity and the motor point of the muscle, where the injection of toxin exerts its maximal effect. Consequently, lower doses of BTA can be employed without decreasing the efficacy of treatment but reducing the potential risk of side effects, antibody production and the cost of treatment. Electrophysiological diagnosis and BTA treatment may be performed during the same exploration. Considerations on the particular aspects and lines of action are given referring to the main focal muscular hyperactivity motor disorders such as cervical, oromandibular and laryngeal dystonias, blepharospasm, writer's cramp, hemifacial and hemimasticatory spasms, infantile and adult forms of spasticity and some other focal disturbances such as strabismus, detrusor-sphincter dyssynergia and anismus.
authors.affiliation: Department of Clinical Neurophysiology, Hospital General Universitario Gregorio-Marañón, C/Dr. Esquerdo, 46, 28007 Madrid, Spain. neurofis@ipmq.hggm.es
authors.forename: A
authors.initials: A
authors.lastname: Traba López
authors.forename: A
authors.initials: A
authors.lastname: Esteban
mesh_terms: D018726:Anti-Dyskinesia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000494:pharmacology / Q000627:therapeutic use*; D004576:Electromyography; D006801:Humans; D009069:Movement Disorders / Q000188:drug therapy*; D009469:Neuromuscular Junction / Q000187:drug effects / Q000502:physiology
chemical_list: D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins